Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer.
Zhiguo ZhaoPratik A PatelLeonora SlatnickJitsuda Sitthi-AmornKevin J BielamowiczFarranaz A NunezAlexandria M WalshJennifer HessJenna RossoffCaitlin W ElgartenRegina M MyersRaya SaabMaya BasbousMeghan MccormickCatherine AftandilianRebecca RichardsCharles Nathaniel NessleAlison C TribbleJessica K Sheth BhutadaScott L CovenDaniel V RuncoJennifer J WilkesArun GurunathanTerri GuiniperoJennifer A BelskyKaren LeeVictor WongMegha MalhotraAmy E ArmstrongLauren P JerkinsShane J CrossLyndsay FisherMadison T SteinNatalie L WuTroy YiEtan OrgelGabrielle M HaeuslerJoshua WolfJenna M SopfeTamara P MillerAdam J EsbenshadePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The EsVan models, especially EsVan2b, perform very well prospectively across multiple academic medical centers and accurately stratify risk of BSI in episodes of non-neutropenic fever in pediatric patients with cancer. Implementation of routine screening with risk-stratified management for non-neutropenic fever in pediatric patients with cancer could safely reduce unnecessary antibiotic use.